Literature DB >> 18159305

How Nova Scotia general practitioners choose antibiotics for the empirical treatment of community-acquired pneumonia.

J Pendergrast1, T J Marrie.   

Abstract

OBJECTIVE: To gain an understanding of how physicians in general practice choose antibiotics for the empirical treatment of community-acquired pneumonia (CAP).
DESIGN: Questionnaire with three sample cases of CAP and a knowledge assessment (mailed to half of the physicians). POPULATION STUDIED: Nova Scotia family physicians.
RESULTS: One hundred and eighty-four of the 841 (21.9%) physicians who were mailed a questionnaire responded. A knowledge assessment showed satisfactory knowledge except in two areas - an overestimation of the prevalence of penicillin-resistant Streptococcus pneumoniae in Nova Scotia and the view that ciprofloxacin was an effective antibiotic for the treatment of CAP (42% of physicians). As the complexity of the case increased, there was decreasing consensus regarding the choice of antibiotic therapy and a decline in prescribing according to guidelines for the treatment of CAP. Also, as the complexity of the cases increased, it became increasingly difficult to discern a decision-making strategy. For the simplest case - a 17-year-old male with presumed Mycoplasma pneumoniae pneumonia - physician factors (age, family practice training), desire to target specific pathogens, and concern with resistance and side effects affected the choice of antibiotic. However, for the most complex case - a 45-year-old female with severe pneumonia - familiarity with such a case was the only significant factor and led to treatment with a combination of antibiotics designed to treat both typical and atypical pathogens.
CONCLUSIONS: For uncomplicated cases of CAP, physician factors, desire to treat specific pathogens and concern with resistance affect the choice of antibiotic therapy. For complex cases, familiarity with such cases was the only factor that influenced choice of antibiotic therapy.

Entities:  

Keywords:  Antibiotics; Community-acquired pneumonia; Decision-making; Empirical treatment; General practitioners

Year:  2000        PMID: 18159305      PMCID: PMC2094787          DOI: 10.1155/2000/751034

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  20 in total

1.  Reasons for choice of antibiotic for the empirical treatment of CAP by Canadian infectious disease physicians.

Authors:  J Pendergrast; T Marrie
Journal:  Can J Infect Dis       Date:  1999-09

Review 2.  Clinical judgment analysis.

Authors:  J R Kirwan; D M Chaput de Saintonge; C R Joyce
Journal:  Q J Med       Date:  1990-09

Review 3.  Written case simulations: do they predict physicians' behavior?

Authors:  T V Jones; M S Gerrity; J Earp
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

4.  The value of routine microbial investigation in community-acquired pneumonia.

Authors:  M A Woodhead; J Arrowsmith; R Chamberlain-Webber; S Wooding; I Williams
Journal:  Respir Med       Date:  1991-07       Impact factor: 3.415

5.  Towards understanding treatment preferences of hospital physicians.

Authors:  P Denig; F M Haaijer-Ruskamp; H Wesseling; A Versluis
Journal:  Soc Sci Med       Date:  1993-04       Impact factor: 4.634

6.  Rationales expressed by empiric antibiotic prescribers.

Authors:  C D Hepler; K E Clyne; S T Donta
Journal:  Am J Hosp Pharm       Date:  1982-10

7.  Prescribers' beliefs and values as predictors of drug choices.

Authors:  R Segal; C D Hepler
Journal:  Am J Hosp Pharm       Date:  1982-11

8.  The relationship between physician characteristics and prescribing appropriateness.

Authors:  P D Stolley; M H Becker; L Lasagna; J D McEvilla; L M Sloane
Journal:  Med Care       Date:  1972 Jan-Feb       Impact factor: 2.983

9.  Antibiotic choice and patient outcomes in community-acquired pneumonia.

Authors:  W J Hueston; M A Schiaffino
Journal:  J Am Board Fam Pract       Date:  1994 Mar-Apr

Review 10.  Empirical therapy of community-acquired pneumonia.

Authors:  M S Niederman
Journal:  Semin Respir Infect       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.